SLC2A1 and pancreatic neoplasm: The glucose transporter GLUT1 is highly expressed in glycolytic tumors, such as KRAS mutated pancreatic cancers, yet our SILAC experiments show that it is further upregulated upon CD147 knockdown (Figure 3A).